Avandia critics have focused on the dearth of evidence suggesting any advantage for rosiglitazone when compared to pioglitazone. They argue that there is no good reason for anyone to take rosiglitazone instead of pioglitazone. This view receives some support from the systematic review of controlled epidemiologic studies of cardiovascular risk in patients treated with rosiglitazone or pioglitazone by Kate Gelperin, Esther Zhou and David J. Graham from the Office of Surveillance and Epidemiology. (See our previous posts here and here for additional coverage of the briefing material.)
Here are the authors’ conclusions and 3 key Forest plots (click to enlarge):
AUTHORS’ CONCLUSIONS
Speak Your Mind